Search For "sirolimus drug eluting balloon"
"Revolutionizing Heart Care & Empowering Patients:" Sirolimus-Driven Ballo
Updated : 6 months, 1 week ago IST
San Francisco [US], November 19: In a defining chapter for global cardiovascular care, MedAlliance, the Swiss-based innovator behind the patented SELUTION Sirolimus Drug-Eluting Balloon (DEB), continues to transform the landscape of heart disease treatment following its acquisition by Cordis
Read More
MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTI
Updated : 2 years, 8 months ago IST
Geneva [Switzerland], September 15: MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel siroli
Read More
Over 1,000 patients enrolled in Landmark SELUTION DeNovo Study
Updated : 3 years, 2 months ago IST
Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment st
Read More
MedAlliance announces completion of enrollment in Japanese SELUTION SLR
Updated : 4 years, 8 months ago IST
Geneva [Switzerland], September 23 (ANI/PRNewswire): MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD).
Read More
MedAlliance announces first patient enrolled in the 3,300 Patient Landmark
Updated : 4 years, 9 months ago IST
Geneva [Switzerland], September 1 (ANI/PRNewswire): MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study "SELUTION DeNovo". This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], ver
Read More
MedAlliance announces enrollment of first patient in erectile dysfunction
Updated : 4 years, 9 months ago IST
Nyon [Switzerland], August 19 (ANI/PRNewswire): MedAlliance has announced enrollment of the first patient in an erectile dysfunction (ED) feasibility study with its sirolimus drug-eluting balloon [DEB].
Read More
MedAlliance announces completion of enrolment in PRISTINE clinical trial w
Updated : 4 years, 9 months ago IST
Nyon [Switzerland], August 13 (ANI/PRNewswire): MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of patients with Below-the-Knee (BTK) disease.
Read More
MedAlliance gains CE Mark approval for coronary SELUTION SLR™ Siroli
Updated : 5 years, 11 months ago IST
Mumbai (Maharashtra) [India] June 16 (ANI/PRNewswire): MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease.
Read More